tetano
Editor, Senior Moderator
Pediatrics
. 2023 Feb 1;151(2):e2022059037.
doi: 10.1542/peds.2022-059037.
Codetections of Other Respiratory Viruses Among Children Hospitalized With COVID-19
Nickolas T Agathis[SUP] 1 2 [/SUP], Kadam Patel[SUP] 2 3 4 [/SUP], Jennifer Milucky[SUP] 2 3 [/SUP], Christopher A Taylor[SUP] 2 3 [/SUP], Michael Whitaker[SUP] 2 3 [/SUP], Huong Pham[SUP] 2 3 [/SUP], Onika Anglin[SUP] 2 3 4 [/SUP], Shua J Chai[SUP] 5 6 [/SUP], Nisha B Alden[SUP] 7 [/SUP], James Meek[SUP] 8 [/SUP], Evan J Anderson[SUP] 9 10 11 [/SUP], Andy Weigel[SUP] 12 [/SUP], Sue Kim[SUP] 13 [/SUP], Ruth Lynfield[SUP] 14 [/SUP], Chad Smelser[SUP] 15 [/SUP], Alison Muse[SUP] 16 [/SUP], Kevin Popham[SUP] 17 [/SUP], Laurie M Billing[SUP] 18 [/SUP], Melissa Sutton[SUP] 19 [/SUP], H Keipp Talbot[SUP] 20 [/SUP], Andrea George[SUP] 21 [/SUP], Meredith McMorrow[SUP] 2 3 22 [/SUP], Fiona P Havers[SUP] 2 3 22 [/SUP]; CDC COVID-NET Surveillance Team
Collaborators, Affiliations
Abstract
Objectives: To assess the clinical impact of respiratory virus codetections among children hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Methods: During March 2020 to February 2022, the US coronavirus disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET) identified 4372 children hospitalized with SARS-CoV-2 infection admitted primarily for fever, respiratory illness, or presumed COVID-19. We compared demographics, clinical features, and outcomes between those with and without codetections who had any non-SARS-CoV-2 virus testing. Among a subgroup of 1670 children with complete additional viral testing, we described the association between presence of codetections and severe respiratory illness using age-stratified multivariable logistic regression models.
Results: Among 4372 children hospitalized, 62% had non-SARS-CoV-2 respiratory virus testing, of which 21% had a codetection. Children with codetections were more likely to be <5 years old (yo), receive increased oxygen support, or be admitted to the ICU (P < .001). Among children <5 yo, having any viral codetection (<2 yo: adjusted odds ratio [aOR] 2.1 [95% confidence interval [CI] 1.5-3.0]; 2-4 yo: aOR 1.9 [95% CI 1.2-3.1]) or rhinovirus/enterovirus codetection (<2 yo: aOR 2.4 [95% CI 1.6-3.7]; 2-4: aOR 2.4 [95% CI 1.2-4.6]) was significantly associated with severe illness. Among children <2 yo, respiratory syncytial virus (RSV) codetections were also significantly associated with severe illness (aOR 1.9 [95% CI 1.3-2.9]). No significant associations were seen among children ≥5 yo.
Conclusions: Respiratory virus codetections, including RSV and rhinovirus/enterovirus, may increase illness severity among children <5 yo hospitalized with SARS-CoV-2 infection.
. 2023 Feb 1;151(2):e2022059037.
doi: 10.1542/peds.2022-059037.
Codetections of Other Respiratory Viruses Among Children Hospitalized With COVID-19
Nickolas T Agathis[SUP] 1 2 [/SUP], Kadam Patel[SUP] 2 3 4 [/SUP], Jennifer Milucky[SUP] 2 3 [/SUP], Christopher A Taylor[SUP] 2 3 [/SUP], Michael Whitaker[SUP] 2 3 [/SUP], Huong Pham[SUP] 2 3 [/SUP], Onika Anglin[SUP] 2 3 4 [/SUP], Shua J Chai[SUP] 5 6 [/SUP], Nisha B Alden[SUP] 7 [/SUP], James Meek[SUP] 8 [/SUP], Evan J Anderson[SUP] 9 10 11 [/SUP], Andy Weigel[SUP] 12 [/SUP], Sue Kim[SUP] 13 [/SUP], Ruth Lynfield[SUP] 14 [/SUP], Chad Smelser[SUP] 15 [/SUP], Alison Muse[SUP] 16 [/SUP], Kevin Popham[SUP] 17 [/SUP], Laurie M Billing[SUP] 18 [/SUP], Melissa Sutton[SUP] 19 [/SUP], H Keipp Talbot[SUP] 20 [/SUP], Andrea George[SUP] 21 [/SUP], Meredith McMorrow[SUP] 2 3 22 [/SUP], Fiona P Havers[SUP] 2 3 22 [/SUP]; CDC COVID-NET Surveillance Team
Collaborators, Affiliations
- PMID: 36995184
- DOI: 10.1542/peds.2022-059037
Abstract
Objectives: To assess the clinical impact of respiratory virus codetections among children hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Methods: During March 2020 to February 2022, the US coronavirus disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET) identified 4372 children hospitalized with SARS-CoV-2 infection admitted primarily for fever, respiratory illness, or presumed COVID-19. We compared demographics, clinical features, and outcomes between those with and without codetections who had any non-SARS-CoV-2 virus testing. Among a subgroup of 1670 children with complete additional viral testing, we described the association between presence of codetections and severe respiratory illness using age-stratified multivariable logistic regression models.
Results: Among 4372 children hospitalized, 62% had non-SARS-CoV-2 respiratory virus testing, of which 21% had a codetection. Children with codetections were more likely to be <5 years old (yo), receive increased oxygen support, or be admitted to the ICU (P < .001). Among children <5 yo, having any viral codetection (<2 yo: adjusted odds ratio [aOR] 2.1 [95% confidence interval [CI] 1.5-3.0]; 2-4 yo: aOR 1.9 [95% CI 1.2-3.1]) or rhinovirus/enterovirus codetection (<2 yo: aOR 2.4 [95% CI 1.6-3.7]; 2-4: aOR 2.4 [95% CI 1.2-4.6]) was significantly associated with severe illness. Among children <2 yo, respiratory syncytial virus (RSV) codetections were also significantly associated with severe illness (aOR 1.9 [95% CI 1.3-2.9]). No significant associations were seen among children ≥5 yo.
Conclusions: Respiratory virus codetections, including RSV and rhinovirus/enterovirus, may increase illness severity among children <5 yo hospitalized with SARS-CoV-2 infection.